Hologram QSAR model for the prediction of human oral bioavailability.

A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical development of many otherwise promising drug candidates. A variety of in silico ADME (absorption, distribution, metabolism, and excretion) models are receiving increased attention due to a better appreciation that pharmacokinetic properties should be considered in early phases of the drug discovery process. Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects. In the present work, hologram quantitative structure-activity relationships (HQSAR) were performed on a training set of 250 structurally diverse molecules with known human oral bioavailability. The most significant HQSAR model (q(2)=0.70, r(2)=0.93) was obtained using atoms, bond, connection, and chirality as fragment distinction. The predictive ability of the model was evaluated by an external test set containing 52 molecules not included in the training set, and the predicted values were in good agreement with the experimental values. The HQSAR model should be useful for the design of new drug candidates having increased bioavailability as well as in the process of chemical library design, virtual screening, and high-throughput screening.

[1]  Donald E Mager,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships. , 2006, Advanced drug delivery reviews.

[2]  Søren Brunak,et al.  Prediction methods and databases within chemoinformatics : Emphasis on drugs and drug candidates , 2005 .

[3]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[4]  Glaucius Oliva,et al.  Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[5]  Berith F. Jensen,et al.  In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. , 2007, Journal of medicinal chemistry.

[6]  H. Mewes,et al.  Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.

[7]  Marcelo Santos Castilho,et al.  Classical and Hologram QSAR Studies on a Series of Tacrine Derivatives as Butyrylcholinesterase Inhibitors , 2007 .

[8]  Adriano D Andricopulo,et al.  Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. , 2005, Bioorganic & medicinal chemistry letters.

[9]  Sean Ekins,et al.  Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. , 2005, Trends in pharmacological sciences.

[10]  S. O'Brien,et al.  Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.

[11]  Corwin Hansch,et al.  QSAR and ADME. , 2004, Bioorganic & medicinal chemistry.

[12]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[13]  Franco Lombardo,et al.  In silico ADME prediction: data, models, facts and myths. , 2003, Mini reviews in medicinal chemistry.

[14]  A. Beresford,et al.  The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.

[15]  Adriano D Andricopulo,et al.  Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. , 2007, Journal of molecular graphics & modelling.

[16]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[17]  G. Oliva,et al.  Structure-activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase. , 2004, Bioorganic & medicinal chemistry letters.

[18]  C. Hansch,et al.  Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. , 2001, Chemical reviews.

[19]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[20]  Kwang S. Kim,et al.  Homology modeling and molecular dynamics study of chorismate synthase from Shigella flexneri. , 2006, Journal of molecular graphics & modelling.

[21]  Kenneth C Saunders,et al.  Automation and robotics in ADME screening. , 2004, Drug discovery today. Technologies.